全身糖皮质激素降低IgA肾病中IgA及半乳糖缺陷型IgA1水平的作用
基于治疗性试验中国队列137例样本,检测基线、6及12个月血清总IgA和Gd-IgA1。与安慰剂比,减量组6个月IgA降27.2%、Gd-IgA1降21.2%,全量组分别降34%和42.7%。12个月减量组Gd-IgA1降4.6%(P=0.47),全量组维持降25.4%(P<0.001)。Gd-IgA1降低与蛋白尿减少相关,但6个月Gd-IgA1降低与长期肾脏结局无关(P=0.49)。
要点
- 全身糖皮质激素可降低IgA肾病患者总IgA和Gd-IgA1水平,但停药后效应减弱。
- Gd-IgA1降低与甲泼尼龙组蛋白尿减少呈正相关,安慰剂组无显著相关。
- 治疗6个月时Gd-IgA1降低与长期肾脏进展事件无关(P=0.49)。
核心结论
- 与安慰剂相比,全身糖皮质激素显著降低IgA肾病患者的血清总IgA和Gd-IgA1水平,但治疗效应可能随时间减弱。
研究设计与样本
- 基于治疗性试验(NCT01560052)中国队列137例参与者的血清样本,于基线、6个月和12个月检测总IgA和Gd-IgA1水平。
- 采用线性混合模型比较各治疗组从基线至6个月和12个月的总IgA和Gd-IgA1变化。
主要发现
- 6个月时,减量组较安慰剂组总IgA降低27.2%(95%CI 16.4%至36.6%),Gd-IgA1降低21.2%(95%CI 10.6%至30.6%)。
- 6个月时,全量组较安慰剂组总IgA降低34%(95%CI 25.7%至41.4%),Gd-IgA1降低42.7%(95%CI 36.1%至48.6%)。
- 12个月时,减量组Gd-IgA1较安慰剂组降低4.6%(95%CI −8.3%至15.9%,P=0.47),全量组维持降低25.4%(95%CI 16.8%至33.1%,P<0.001)。
- 在甲泼尼龙组中,总IgA和Gd-IgA1变化与蛋白尿减少呈正相关,而安慰剂组无显著相关性。
- 6个月时Gd-IgA1水平降低与长期肾脏进展事件无关(P=0.49)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Systemic glucocorticoids could reduce levels of total IgA and galactose-deficient IgA1 (Gd-IgA1) in IgA nephropathy patients, but the effect diminished after treatment discontinuation. The reduction in Gd-IgA1 levels correlates with a decrease in proteinuria in patients treated with glucocorticoids. However, the reduction in Gd-IgA1 levels at 6 months during the treatment is not associated with long-term kidney outcomes. BACKGROUND: The Therapeutic Effects of Steroids in IgA Nephropathy Global trial demonstrated that glucocorticoid therapy reduced proteinuria and improved kidney outcomes in patients with IgA nephropathy. Galactose-deficient IgA1 (Gd-IgA1) plays a central role in IgA nephropathy pathogenesis by promoting immune complex formation. However, the effects of glucocorticoid on pathogenic IgA levels remain unclear. This study aimed to evaluate the effect of systemic glucocorticoids on serum total IgA and Gd-IgA1 levels in patients with IgA nephropathy in the Therapeutic Effects of Steroids in IgA Nephropathy Global trial. METHODS: Serum samples from 137 participants in the China Cohort were collected at baseline, 6, and 12 months. We measured the levels of total IgA and Gd-IgA1. The association between the changes in these markers and proteinuria reduction was analyzed. A linear mixed model was used to compare the changes in total IgA and Gd-IgA1 across each arm from baseline at 6 and 12 months. RESULTS: At 6 months, the reduced dose group showed a 27.2% (95% confidence interval, 16.4% to 36.6%) reduction in IgA and a 21.2% (10.6% to 30.6%) reduction in Gd-IgA1 compared with the placebo group. The full dose group exhibited reductions of 34% (25.7% to 41.4%) and 42.7% (36.1% to 48.6%), respectively. At 12 months, Gd-IgA1 decrement in the reduced dose group were similar compared to placebo by 4.6% (−8.3% to 15.9%, P = 0.47), while the full dose group maintained a significant reduction of 25.4% (16.8% to 33.1%, P < 0.001). A positive correlation was found between changes in total IgA, Gd-IgA1, and proteinuria reduction in the methylprednisolone groups, whereas no significant correlation was observed in the placebo group. The reduction in Gd-IgA1 levels at 6 months was not associated with long-term kidney progression events (P = 0.49). CONCLUSIONS: Systemic glucocorticoids significantly reduce total IgA and Gd-IgA1 levels in IgA nephropathy compared with placebo; however, the treatment effects may diminish over time. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: NCT01560052.
引用
- Zan J, Li J, Wong MG, et al. Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy. Clin J Am Soc Nephrol. 2025. PMID: 40924482. doi:10.2215/CJN.0000000816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。